Evernorth PBS 2027 PBM Season Shows Renewals Strength, New Business Momentum, and Specialty Upside

Summary of the 2027 PBM selling season (renewals vs. new business), and specialty incremental opportunities / contracting changes

1) Renewals and “where renewals are at”

The excerpts do not provide a precise renewal count, retention rate broken out between renewals vs. new business, or specific dollars tied to renewals for the 2027 selling season. What is explicitly disclosed is retention for Evernorth Pharmacy Benefit Services (PBS) and an indication that 2027 is tracking at historically strong levels:

• 2026 PBS retention was over 97%, and preliminary indicators for 2027 suggest mid-90s or higher retention, described as consistent with historical norms. ¹

Management also characterizes customers’ behavior as showing multiyear partner demand as clients prepare for “future changes in their Pharmacy Benefit Programs,” which supports the idea that renewals/renewal discussions are being driven by a multi-year contracting view rather than short-term selection. ²

2) New business wins: how they sized them in the selling season

While the excerpts don’t give a detailed contract-by-contract table, they do quantify the relative strength of new business:

• Total new business already secured is above the prior two selling seasons combined, characterized as “a very strong ’27 new business performance.” ¹
• Management also emphasizes that adding value and “winning business today” with 2027 representing one of Evernorth PBS’s strongest selling seasons in recent years. ³
• Separately, management frames incremental interest from health plans and employers in the company’s Signature (rebate-free) model, including significant early interest ahead of the broader 2028 launch and introducing Signature to Cigna Healthcare’s fully insured plans next year (2027). ³

3) Incremental opportunities within Specialty (what was seen in Specialty during selling)

The excerpts indicate Specialty is benefiting from underlying market dynamics (specialty utilization growth, biosimilars/specialty generics adoption) and that Specialty & Care performance is strong, which tends to increase the addressable economics for incremental Specialty-related contracting within Evernorth’s platform.

3a) Market/offer traction in Specialty & Care

Specific, qualitative-and-quantitative signals from the excerpts include:

• Management describes “phenomenal” Specialty growth in the first half and expects continued strong results for the back half, driven by faster-than-expected adoption of biosimilars and specialty generics improving operating efficiency and continued strength in specialty utilization. ⁴
• They state Specialty & Care’s second-quarter performance exceeded expectations, with performance driven by continued strength in specialty utilization and faster-than-expected adoption of biosimilars/specialty generics. ⁵
• A concrete adoption metric: Specialty generic penetration exceeded 80% for newer products during the quarter. ⁵
• Management expects specialty generics and biosimilars to be a meaningful tailwind as it looks through the back half of the year. ⁵

3b) Is Specialty incrementality coming via carve-outs vs broader PBM contracting?

The direct question in the transcript asks whether there are “carve-outs” or whether the incremental Specialty opportunity is primarily “winning more business” or “incremental business through the PBM contracting.” ⁶

However, the excerpts provided do not explicitly state whether 2027 Specialty incrementality is coming from carve-outs versus broader PBM contracting. What is explicit is the direction of the business model and customer behavior:

• Management says clients view Cigna as a multiyear thought partner preparing for future PBM changes, and it is “pleased with the performance so far in the ’27 season.” ⁷
• Management also ties platform breadth (Specialty & Care + network option and offerings) to market needs, including Accredo Specialty Pharmacy being included as a network option and “even more unaffiliated PBM offerings,” which indicates expansion through network/options availability and broader platform inclusion rather than stating carve-outs. ⁷
• Management further attributes Evernorth platform adaptation to market needs, stating solutions are adapting and that the company is confident in long-term durability, but it does not explicitly categorize incremental Specialty sourcing as carve-outs. ⁷

Net: based strictly on the provided excerpts, carve-outs are not confirmed; the evidence supports strong Specialty uptake driven by biosimilars/specialty generics adoption and platform/network inclusion within PBM contracting. ⁶⁷⁵

4) Any broader PBM contracting changes (including “Signature” transition mechanics)

The excerpt set repeatedly references broader structural PBM contracting change via the transition to the rebate-free Signature model and related recontracting dynamics.

4a) Signature model: timing and market/contracting shift

Key disclosed points:

• Management calls Signature a new rebate-free Signature model and states it is generating considerable interest from existing clients and prospects as they plan ahead to scale it in 2028 and beyond. ¹
• Management describes Signature’s alignment with federal requirements: it is fully aligned with Consolidated Appropriations Act provisions effective in mid-2028, and management says they went beyond the regulatory minimum to simplify pharmacy benefits. ⁸
• The insured book early adoption timing is explicit: Signature is planned to be introduced to Cigna Healthcare fully insured plans next year (2027) and scaled in 2028, with Cigna Healthcare’s insured book as “early adopters in 2027.” ²³
• Management says they expect Signature to yield margins in the ~4% range, similar to legacy PBS margins. ²

4b) Selling season “and other levels of recontracting”

While the excerpts do not provide a detailed calendar of recontracting milestones, they do acknowledge broader multi-step contracting activity:

• The transcript explicitly references that beyond the selling season, there are other renegotiation processes including pharma company negotiations and pharmacy negotiations as part of the transition progressing relative to plan. ⁹
• The provided management answer then focuses on Signature build-out, stakeholder fiduciary obligations, and the operational mechanics of the model (price-assured capability; cost-plus dynamic dispensing fee for pharmacies). ²⁸

4c) Renewals vs transition economics (PBS financial mechanics)

The earnings excerpts also describe how the broader market drug mix and the platform reallocation affects PBS vs Specialty & Care economics:

• Management explains that specialty generics and biosimilars create a margin benefit for Evernorth overall, but that there is an “economic shift” from PBS to Specialty & Care, with drug costs lower and therefore “not a proportional increase in the revenue line.” ¹⁰
• They also specifically say the PBM side sees lower results in Pharmacy Benefit Services with higher results in Specialty & Care, and they frame this as how it “all comes together.” ¹⁰

Additionally, they discuss GLP-1 dynamics affecting PBS volumes:

• They mention deceleration in GLP-1 prescription growth creating modest downward pressure on PBS financial picture in the quarter, while strength in Specialty offsets overall Evernorth results. ¹¹
• They also quantify that in Cigna Healthcare’s book only 15% to 20% covers GLP-1s for weight management (because many smaller employers don’t cover GLP-1 for weight management), which helps explain why GLP-1 affordability decisions produce only modest exposure in Cigna Healthcare. ¹¹

5) What this implies for the 2027 selling season balance (renewals + new business + specialty incrementality + contracting change)

Putting the explicit excerpted facts together:

• Renewals: PBS retention is disclosed at >97% in 2026 and mid-90s+ expected/indicated for 2027, which is consistent with historical norms—this is evidence of healthy renewal performance, even though the excerpt doesn’t split renewals dollar-by-dollar for 2027. ¹
• New business wins: 2027 new business momentum is strong, with total new business already secured above the prior two selling seasons combined and characterized as one of the strongest selling seasons in recent years. ¹³
• Specialty incremental opportunities: Specialty & Care is described as delivering strong performance and benefiting from biosimilars/specialty generics adoption (including >80% specialty generic penetration for newer products in the quarter). ⁵
• Carve-outs vs broader contracting: The excerpts do not explicitly confirm carve-outs. The available evidence points more toward platform/network inclusion and multi-year contracting discussions supporting Specialty uptake alongside PBM contracting changes (rather than a stated carve-out strategy). ⁶⁷
• Broader contracting changes: The key structural change highlighted is the rebate-free Signature model transition, aligned to mid-2028 regulatory effectiveness with early adoption in 2027 for Cigna Healthcare fully insured, and scaling in 2028—with explicit claims that market feedback/interest is positive and that clients are engaging because of fiduciary obligations and desire for budget predictability. ²⁸³

Bottom line: The provided excerpts support that Evernorth/PBS is entering the 2027 season with very strong renewal retention (mid-90s+ indicated) and exceptionally strong new business momentum (new business above the prior two selling seasons combined), while Specialty incremental opportunity appears strong and is being driven by biosimilars/specialty generics adoption and Specialty & Care execution rather than a stated carve-out strategy; the broader PBM contracting change center is the Signature rebate-free transition, with positive stakeholder interest and a phased timeline (insured plans in 2027; scale in 2028). ¹⁵²³